The role of state anxiety in the development of anticipatory nausea and vomiting (ANV) in cancer chemotherapy has been the focus of considerable empirical investigation and theoretical speculation. However, while some relationship between state anxiety and ANV is presumed to exist, determination of its precise nature has proven elusive. Specific hypotheses linking state anxiety to ANV are described and evaluated in light of the empirical evidence. These hypotheses include (a) ANV is a symptomatic concomitant of state anxiety; (b) state anxiety directly facilitates the classical conditioning of ANV; (c) state anxiety exacerbates the magnitude of post-treatment nausea and vomiting experienced, thus increasing the risk of ANV; (d) ANV causes infusion-related state anxiety; and (e) the observed relationship between ANV and state anxiety is a result of methodological artifact. It is concluded that state anxiety can play a causal role in the development of ANV in some patients. In particular, the hypothesis that state anxiety exacerbates post-treatment nausea and vomiting and thus increases the risk for ANV appears best supported by the data. Finally, the clinical implications of the relationship between ANV and state anxiety for the treatment and prevention of ANV are discussed.
INTRODUCTION
Recent years have witnessed increasing interest in the interface of psychosocial and biological processes in the development and treatment of cancer. Within this field of biopsychosocial oncology (1) , anticipatory nausea and vomiting (ANV) has received considerable attention (2) (3) (4) . While many patients receiving intravenous cytotoxic chemotherapy experience gastrointestinal distress following their infusions, ANV refers to the nausea and vomiting that some patients experience prior to their infusions.
ANV is interesting because it is both clinically and theoretically significant. ANV is a relatively common symptom. Prevalence estimates have ranged up to 65% (5) of all chemotherapy patients but it appears that about 25-50% of all patients experience ANV (2) (3) (4) . Furthermore, ANV can be both physically and psychologically stressful, compromising quality of life as well as influencing some patients to discontinue chemotherapy (6) . Theoretical interest in ANV stems from attempts to understand its etiology. While post-treatment nausea and vomiting (PNV) is presumed to be a primarily pharmacological side effect of chemotherapy, ANV is viewed as a learned response. Over the course of chemotherapy, certain visual, olfactory, taste, and auditory stimuli are consistently associated with drug infusion and subsequent gastrointestinal distress. Eventually, in vivo exposure to these stimuli alone is sufficient to trigger nausea and/or vomiting in some patients. In some instances, even cognitive stimuli, such as the thought of chemotherapy, can elicit these symptoms. Evidence supporting this classical conditioning model of acquisition has accumulated in recent years and this etiological account has received wide acceptance (2) .
Although classical conditioning provides a general account of the development of ANV, identification of the specific conditions which facilitate or impede this learning process has been a challenge.
Since not all chemotherapy patients develop ANV, considerable effort has been devoted to identifying factors which characterize patients who develop ANV. A variety of patient, disease, and treatmentrelated variables have been examined. Consistent with a conditioning model, the presence and severity of PNV has emerged as the major factor in ANV development (7) (8) (9) (10) (11) (12) (13) .
Despite the pre-eminence of PNV, other factors are also involved in the development of ANV. For example, elevated levels of trait anxiety (13) , state anxiety (7, 8, 12, 14, 15) , and general "distress" (13) have been found to characterize patients who experience ANV. Accordingly, the role of anxiety has been a major focus of empirical investigation as well as theoretical speculation (2, 16, 17) . In addition to increasing theoretical understanding of ANV development, identification of the relationship between ANV and anxiety has clear clinical implications. If elevated levels of state anxiety are causally related to ANV, anxiety-reducing interventions could then prevent or delay the development of ANV (18) .
While some relationship between ANV and anxiety is presumed to exist, determination of its precise nature has remained elusive. A number of different relationships between ANV and state anxiety have been hypothesized (2, 4, 17, 32,,33) . However, little attempt has been made to review and evaluate the existing research in light of these hypotheses. This paper will examine the empirical evidence bearing upon the relationship between anxiety and ANV. While isolation of this single correlate of ANV overlooks the potential interaction of anxiety with other variables in the chemotherapy context, focusing attention upon the relationship of anxiety to ANV allows a much more detailed analysis than available in previous reviews. The analysis will proceed in four parts. First, the psychophysiological processes involved in the experience of nausea and vomiting will be discussed. Second, the research investigating the relationship between anxiety and ANV will be reviewed and summarized. Third, hypotheses regarding the relationship between state anxiety and ANV will be described and critically examined in light of the empirical evidence. Finally, the clinical implications of the ANV-anxiety relationship will be considered.
PSYCHOPHYSIOLOGY OF NAUSEA AND VOMITING
To appreciate the relationship between ANV and anxiety it is necessary to understand the psychophysiological mechanisms involved in the experience of nausea and vomiting. The emetic process involves a coordinated sequence of events involving both respiratory and gastrointestinal structures (19) (20) (21) (22) . Initiation and coordination of this process is the responsibility of the vomiting center, a structure located in the lateral reticular formation of the medulla. Afferent input from several sources is capable of initiating the emetic process. In addition to physiological input from the vestibular system, pharynx and gastrointestinal tracts, and chemoreceptor trigger zone, psychological stimuli are also capable of eliciting nausea and vomiting. Higher brain stem and cortical structures provide direct input to the vomiting center. Thus, nausea or vomiting may be elicited by diverse circumstances such as the sight of blood or other injury, the sight of another person vomiting, or even the thought of a food or situation that has previously been associated with nausea or vomiting. Such afferent stimulation of the vomiting center via psychological pathways is fundamental to the classical conditioning model of ANV.
Innervation of the vomiting center via psychological pathways is also evidenced by the ability of emotional states, such as state anxiety, to trigger nausea and vomiting (23) (24) (25) . This can account for the occurrence of such symptoms in athletes or thespians prior to competition or performance (26) . The precise neuropsychological mechanisms underlying this phenomenon are not completely understood, however. Activation of the stress response initiates a complex physiological process which includes increased sweating and skin conductance, changes in rate and depth of respiration, and changes in gastrointestinal function-secretion, motility, and mucosal vascularity (27) . All of these gastrointestinal changes are correlated with, if not contributory to, the experience of gastrointestinal distress. Thus, nausea and vomiting can be a concomitant of state anxiety. Furthermore, since individual differences exist in physiological response to stress (28) (29) (30) , it is presumed that some individuals are more prone than others to experience gastrointestinal distress under stressful conditions.
REVIEW OF THE RESEARCH LITERATURE
Examination of the psychological, medical, and nursing literature through mid-1989 revealed a total of one dozen reports of empirical research which could illuminate the ANV-anxiety relationship (5, 7, 8, (12) (13) (14) (15) (31) (32) (33) (34) (35) . These studies are summarized in Table 1 . All of these studies utilized samples of adult chemotherapy patients. (One additional study (36) employed a sample of pediatric chemotherapy patients and was not included in this listing.) In all instances, examination of the methods of these reports indicated that both ANV and either state anxiety, trait anxiety, or general chemotherapy-related "distress" were assessed.
Cross-Sectional Studies
Seven of the 12 studies were retrospective and reported data from only a single occasion of assess- zzzzz>zz"zzzz (5, 13-15, 31. 34, 35) . In all but one of these studies (35) , patients with anticipatory symptoms were contrasted with patients who did not evidence these symptoms.
In three studies (13) (14) (15) , patients were assessed before a chemotherapy infusion and a measure of state anxiety was obtained. Altmaier et al. (14) found that patients with anticipatory vomiting reported greater state anxiety (as measured by the Affect Adjective Checklist (37)). Similarly, Ingle et al. (15) found that patients with either anticipatory nausea or vomiting were characterized by greater state anxiety scores on the Affect Adjective Checklist, relative to patients without ANV. Finally, van Komen and Redd (13) assessed both state and trait anxiety using the State-Trait Anxiety Inventory (STAI) (38) . Ratings of chemotherapy-related "emotional distress" were also obtained using a side effect questionnaire. Patients with anticipatory nausea or vomiting evidenced greater "emotional distress" and trait anxiety than patients without these symptoms. Although assessed, state anxiety data was not reported and it is therefore assumed that ANV and no-ANV patients did not differ with respect to this variable.
In two studies (5, 34) , retrospective ratings of state anxiety associated with a patient's initial chemotherapy cycle were obtained. Ratings of general distress associated with chemotherapy were also obtained. Using a sample of patients receiving cisplatin-based chemotherapy, Coons et al. (5) reported that patients with ANV reported greater chemotherapy-related general distress. However, ANV and no-ANV patients did not differ with regard to state anxiety associated with their initial chemotherapy cycle. Similar results were obtained by Nerenz et al. (34) , using a sample of patients with malignant lymphoma.
Ahles et al. (31) assessed nausea, state anxiety, and physiological arousal (i.e., heart rate) associated with chemotherapy in patients with either (a) posttreatment nausea and vomiting only, (b) pretreatment nausea and vomiting, or (c) pretreatment nausea. Three patients in each category were examined. Both nausea and state anxiety were assessed using visual analogue scales. Measures of nausea, state anxiety, and heart rate were obtained for four contiguous five-minute periods including: (a) while the patient was alone with the experimenter, (b) in the presence of the chemotherapy drugs, (c) while the chemotherapy nurse prepared for the infusion, and (d) the initial five minutes of treatment. Results revealed that patients with only post-treatment nausea and vomiting evidenced low levels on all three measures. Patients with pretreatment nausea reported elevated levels of nausea and state anxiety but showed no evidence of physiological arousal. In contrast, patients with both pretreatment nausea and vomiting evidenced elevated levels of nausea and state anxiety as well as physiological arousal.
The remaining cross-sectional study (35) assessed chemotherapy-related nausea and state anxiety but did not compare patients with and without anticipatory symptoms. In this study, visual analogue ratings of nausea, vomiting, and state anxiety for four separate time periods were obtained: at home and on the way to the hospital, in the hospital before treatment, during treatment, and in the hospital after treatment. Although prevalence rates for anticipatory nausea, vomiting, and state anxiety were reported, no attempt was made to differentiate patients with or without anticipatory symptoms with respect to state anxiety scores.
Longitudinal Studies
Five of the 12 studies cited in Table 1 utilized prospective and longitudinal research designs (7. 8, 12, 32, 33) . Data were collected prior to a patient's initial chemotherapy infusion as well as at subsequent points during the course of chemotherapy.
Nerenz et al. (12) interviewed 192 patients with breast or malignant lymphoma prior to their initial infusion as well as following their first, second, third, and sixth cycles of chemotherapy. The latter four interviews were conducted when patients returned to the clinic to begin the next treatment cycle. During the interviews, patients were queried regarding the presence of anticipatory nausea or vomiting, state anxiety before infusions, and PNV. Results revealed that state anxiety prior to an infusion was related to the experience of PNV following that infusion. Furthermore, the experience of state anxiety prior to the initial infusion was related to the occurrence of ANV during the first six cycles of chemotherapy. The authors concluded that pre-infusion state anxiety facilitates the acquisition of ANV, given the presence of PNV.
A series of three reports by Andrykowski and his colleagues were derived from a single data set (7, 32, 33) . Each report addressed a distinct research question and analyzed essentially different portions of the overall data set. Patients heterogeneous with regard to diagnosis and chemotherapy regimen were studied. Patients were interviewed immediately before and after each of their chemotherapy infusions. Each patient was interviewed for at least 6 months or until they were no longer receiving chemotherapy. Trait anxiety was assessed prior to the initial infusion. Infusion-related state anxiety was assessed prior to each infusion as was the presence and severity of any pretreatment nausea or vomiting. An initial report (7) investigated the prediction of subsequent ANV development from data obtained at (he initial two infusions. Results revealed that patients who subsequently developed ANV reported greater state anxiety prior to their initial infusion. However, ANV and non-ANV groups did not differ with regard to state anxiety prior to their second infusion. Trait anxiety was unrelated to the development of ANV.
A second report (33) , addressed the question of how ANV develops over time. Differences between patients in the rapidity of ANV onset were examined. Use of a longitudinal research design allowed identification of the specific infusion at which ANV was initially reported. Multiple regression analysis was used to identify variables related to the number of infusions received prior to ANV development. Results revealed that trait anxiety was unrelated to speed of ANV development while infusion-related state anxiety was the best predictor of such. Specifically, greater state anxiety was associated with a slower onset of ANV. That is, patients with generally higher levels of infusion-related state anxiety tended to initially develop ANV later in their course of chemotherapy treatment. Subsequently patients with ANV were divided into early and late onset of ANV groups and infusion-related state anxiety for the three infusions prior to and including ANV onset were compared. Results revealed that patients who developed ANV early in their course of treatment (i.e., fourth cycle or earlier) evidenced very low and stable levels of state anxiety across infusions prior to and including that of ANV onset. State anxiety levels in these patients did not differ from those characteristic of patients without ANV. In contrast, patients with a later onset of ANV evidenced greater state anxiety across infusions prior to ANV onset. Anxiety at the infusion that ANV was first reported was extremely elevated. The authors concluded that state anxiety is not necessary for the development of ANV. However, when present, state anxiety may facilitate the development of ANV in some patients, particularly those who develop these symptoms relatively later in their course of treatment.
A third report by Andrykowski (32) compared patients who did not report pretreatment symptoms (no-PTN) with patients who reported nausea or vomiting prior to an infusion on Day 1 of a new treatment cycle (PTNDl). In addition, a third group of patients was included in the comparison: patients who reported nausea and vomiting prior to an infusion but not prior to a Day-1 infusion (PTN). This latter, less restrictive, yet common, definition of ANV results in a group of patients that may include patients whose anticipatory symptoms might be attributable to pharmacological factors rather than indicate "true" ANV (39) . Discriminant analysis revealed that the PTNDl group was different from both the PTN and no-PTN groups with regard to post-treatment nausea. However, neither trait nor state anxiety were significant predictors of group membership. Furthermore, the intercorrelation between pretreatment state anxiety and nausea ratings obtained at the infusion of initial ANV onset were consistently higher in the PTN group, relative to the PTNDl group. This was evident despite no difference between the two groups in absolute levels of pretreatment nausea and state anxiety. The authors suggested that reports of pretreatment nausea in the PTN group might have resulted from a failure to distinguish state anxiety from nausea.
A final prospective, longitudinal study was also completed by Andrykowski and his colleagues (8) . The research methods employed were virtually identical to those in the research described above. However, in this study, a relatively homogeneous sample of women receiving one of two adjuvant chemotherapy regimens for breast cancer was studied. Results of both univariate and multivariate analyses indicated that trait anxiety was not significantly related to the presence of ANV or the rapidity of its development. Consistent with Andrykowski and Redd (33) , however, stepwise multiple regression analyses suggested that patients with higher levels of state anxiety prior to their initial infusion tended to develop ANV relatively later in their course of chemotherapy treatment.
Summary
The 12 studies described above are methodologically diverse. Critical differences exist with regard to (a) the use of anticipatory vomiting, anticipatory nausea, or either, as the criterion response; (b) how the criterion response of anticipatory symptoms was operationally defined; (c) whether trait or state anxiety was assessed; (d) the specific instruments used to assess state anxiety and ANV; (e) the degree of retrospection required in the assessment of infusionrelated state anxiety and ANV; (f) whether a retrospective or prospective research design was em-ployed; (g) whether a univariate or multivariate analytic strategy was used to examine the relationship between ANV and anxiety; and (h) sample size and hence statistical power. Such methodological variation can have a significant impact upon substantive findings and hence upon conclusions drawn regarding the ANV-anxiety relationship. For example, identification of the relationship between state anxiety and ANV appears to be dependent upon how ANV is operationally defined (39) . Similarly, the difficulty in determining whether state anxiety is a precursor or response to ANV when a retrospective research design is employed is well known. Finally, trait anxiety indicates merely a procJivity for experiencing state anxiety given a stressful situation and not the experience of state anxiety itself. Thus, trait and state anxiety might be differentially related to ANV.
In view of this methodological diversity, it follows that certain studies are methodologically and analytically superior to others. In general, greater credence should be placed in research which: (a) employs a prospective research design (7, 8, 12. 32, 33) , (b) uses a multivariate data analytic strategy (7, 8, 12, 13, 15, 32, 33) , (c) utilizes a definition of ANV that seeks to identify instances of "true" ANV (39) by reducing the possibility that anticipatory symptoms are actually the result of other pharmacological or physiological factors (5, 7, 8, 12, 14, (32) (33) (34) (35) , (d) minimizes the degree of retrospection involved in assessments of ANV and infusion-related state anxiety (7, 8, (31) (32) (33) , and (e) has larger sample sizes and thus greater statistical power (7, 8, 12, 13, 15, 32, 33) . Finally, since all of the hypothesized relationships between ANV and anxiety to be discussed below regard the relationship between state anxiefy and ANV, data regarding measures of state anxiety should be given primary consideration. Based upon these criteria, the best studies from a methodological standpoint appear to be the prospective, longitudinal studies by Nerenz et al. (12) and Andrykowski and his colleagues (7, 8, 32. 33) .
RELATIONSHIPS BETWEEN ANV AND ANXIETY
Potential relationships between anxiety and ANV can be classified with respect to whether they posit this relationship to be causal or artifactual in nature. Within each of these classes, different specific relationships have been suggested. Five specific hypotheses regarding the relationship between and anxiety will be discussed. These five were selected because they have all been previously identified in the literature (2, 4, 17, 32, 33) . While the various hypotheses will be discussed separately, they are not necessarily mutually exclusive. Several processes may operate in concert to produce any observed relationship between anxiety and ANV. Finally, since all of the hypotheses to be discussed posit the relationship between ANV and state anxiety, unless otherwise indicated (i.e., trait anxiety), all references to "anxiety" in the following discussion will refer to state anxiety.
Causal Relationships Between ANV and Anxiety
There are several ways in which anxiety might be causally related to ANV. In evaluating each of the causal hypotheses presented below, it is useful to consider the different ways in which the term "cause" can be used. For example, "cause" can refer to a predisposing factor (i.e., diathesis), which is necessary but not sufficient for some phenomenon to occur. Alternatively, "cause" can refer to a factor which precipitates, or triggers, some phenomenon given appropriate conditions. Finally, "cause" can refer to a factor which contributes to the maintenance of some pre-existing phenomenon.
Anxiety causes ANV. For many patients, chemotherapy is a stressful experience. Anxiety and dread may occur several days prior to an infusion and escalate as chemotherapy draws near. Since gastrointestinal distress is a potential concomitant of the stress response, the experience of nausea and vomiting prior to infusions could be attributed simply to elevated state anxiety prior to infusions. In the simplest form of this hypothesis no learning process is invoked, save perhaps that the chemotherapy infusion process and its aftermath is aversive. This expectation then triggers anxiety prior to subsequent infusions. A more complex version of this hypothesis is compatible with the classical conditioning model of ANV development, however. Specifically, Nerenz et al. (12) suggest that state anxiety can become conditioned to external cues associated with drug infusions. It is this conditioned anxiety which then produces symptoms of gastrointestinal distress prior to infusions. The advantage of this conditioned anxiety version of the anxiety-ANV hypothesis is that it can account for the persistence of nausea and vomiting in patients who are no longer receiving chemotherapy but who are nevertheless exposed to clinic stimuli (40) .
The hypothesis that ANV is simply a concomitant of an individual's physiological response to stress is appealing. Attribution of ANV to "nerves" is common among patients, family members, and physicians alike (9, 11, 41) . For example, Dolgin et al. (9) examined the occurrence of ANV in a sample of pediatric chemotherapy patients and reported that treatment-related anxiety was most commonly cited by both patients and parents as the cause of ANV. Undoubtedly, part of the attraction of this hypothesis lies in the fact that ANV and state anxiety frequently coincide. The clinical observation that patients with ANV commonly display a great deal of infusion-related anxiety is supported by a number of cross-sectional, retrospective studies that have found a significant relationship between reports of ANV and concurrent reports of elevated levels of state anxiety (14, 15) and chemotherapy-related "distress" (13, 34) . Some research also suggests that the perception and appraisal of physical symptoms is based not only upon awareness of some change in internal state but also upon available interpretative schemata (42, 43) . Hence, in seeking an explanation for the experience of nausea or vomiting prior to an infusion, the lay person is likely to settle upon an anxiety-based attribution rather than the less salient classical conditioning attribution.
Although intuitively appealing, empirical support for the hypothesis that ANV is a direct result of state anxiety is lacking. Demonstration that patients who report ANV are also more likely to report elevated levels of infusion-related anxiety or distress, as in the retrospective studies cited above (13) (14) (15) 34) , is insufficient. This research is unable to rule out the possibility that state anxiety levels might be elevated in response to the presence of ANV. Research which has assessed trait or state anxiety prospectively is no more persuasive. Nerenz et al. (12) found that the presence of state anxiety prior to a patient's initial chemotherapy infusion was related to the occurrence of ANV during the first six cycles of therapy. Similarly, Andrykowski et al. (7) reported that patients who developed ANV evidenced greater infusion-related anxiety in association with their initial infusion. However, no differences in state anxiety levels between patients who did or did not develop ANV were present at the second infusion, suggesting that greater emotional lability, rather than absolute levels of infusion-related anxiety, might characterize patients who develop ANV. Trait anxiety was unrelated to the development of ANV.
In contrast, three prospective studies have reported no relationship between either state or trait anxiety and the subsequent development of ANV. Andrykowski et al. (8) (34) reported that patients who experienced anxiety during their initial infusion were no more likely to develop ANV than those who did not. However, in both of these studies, reports of state anxiety at the initial infusion were obtained retrospectively, in some instances, after the conclusion of chemotherapy. This reliance on recall could have introduced some error into the assessments which could have obscured the actual relationship between state anxiety and ANV.
In summary, the anxiety-ANV hypothesis posits state anxiety as a precipitating and maintaining "cause" of ANV. However, no firm evidence supports the hypothesis that ANV is simply a concomitant of infusion-related anxiety or emotional distress. Even if the research consistently found that elevated state anxiety preceded the development of ANV, such findings would still not be completely persuasive. At minimum, the ANV-anxiety hypothesis requires demonstration that elevated levels of state anxiety characterize infusions where ANV actually occurs. Even more persuasive would be within-patient data suggesting that state anxiety covaries with the occurrence or severity of ANV. Obviously, such evidence could only be obtained from a longitudinal study assessing state anxiety levels and the occurrence of ANV across a patient's course of treatment. Unfortunately, existing longitudinal studies (7, 8, 12) were oriented toward prediction of patients who subsequently developed ANV and thus did not track the covariance of ANV and state anxiety across infusions.
In addition to a lack of supporting evidence, some evidence argues against the ANV-anxiety hypothesis. For instance, not one patient with ANV in the studies by Morrow (11) or Nesse et al. (41) reported a previous occurrence of anxietyinduced nausea or vomiting. Further contrary evidence is provided by research on the behavioral reactions of pediatric patients to painful bone marrow aspirations (44) . Although nearly all of the children studied exhibited severe anticipatory anxiety, less than 2% became nauseated or vomited prior to the aspiration procedure. A much higher incidence of preaspiration nausea and vomiting would be predicted by the ANV-anxiety hypothesis. Thus, while state anxiety might account for some instances of ANV, the preponderance of evidence suggests that the anxiety-ANV hypothesis is an untenable explanation for the vast majority of occurrences of these symptoms.
Anxiety facilitates classical conditioning of ANV. Based upon the notion that anxious individuals condition more readily (45) (46) (47) , this hypothesis suggests that infusion-related anxiety directly facilitates the classical conditioning of ANV. This anxiety-conditionability hypothesis is derived from Pavlov's views regarding the physiological bases of personality (48) as well as Hullian learning theory (49) . According to this hypothesis, anxious individuals are characterized by a higher generalized drive level which in turn contributes to increased excitatory potential. The latter, characteristic of the "weak" nervous system, facilitates classical conditioning of a variety of behaviors across a variety of situations (48) . Left unspeci-fied by this hypothesis are the exact mechanisms by which state anxiety facilitates conditioning. However, with regard to ANV, Dolgin and Katz (36) have suggested that autonomic arousal is associated with low stimulus screening and less habituation to environmental stimuli. Anxious patients are presumed to attend more vigilantly to external stimuli in the clinic environment. Thus, state anxiety facilitates classical conditioning by increasing the salience of clinic-related stimuli that can subsequently develop into conditioned stimuli for ANV. Some support for this hypothesis can be found in the research which suggests that norepinephrine, which is elevated in anxiety, enhances selective attention to relevant conditioned stimuli (50) .
Acceptable evidence in support of the anxiety-conditionability hypothesis would involve demonstration that patients who develop ANV, or who develop ANV more rapidly, would be characterized by high levels of trait anxiety or infusion-related state anxiety, particularly early in their course of chemotherapy. Three studies, all employing the STAI, have examined the link between trait anxiety and ANV development. Using a retrospective design, van Komen and Redd (13) reported that patients with ANV evidenced higher trait anxiety relative to patients without ANV. On the other hand, two prospective studies by Andrykowski and his colleagues (7, 8, 33) found that trait anxiety was unrelated to both the likelihood and rapidity of ANV development. However, because trait anxiety only indicates a propensity to experience state anxiety given a stressful or threatening situation, the failure to link trait anxiety with ANV is not as serious a blow to this hypothesis as it might appear. More significant is evidence regarding the link between state anxiety and ANV. As previously indicated, however, the data in this regard are inconsistent. While retrospective studies consistently have found that patients with ANV are characterized by higher current levels of state anxiety or chemotherapy-related distress (13) (14) (15) 34) , prospective data has yielded mixed results. Whereas, two studies (7, 12) found elevated state anxiety at the initial infusion to characterize patients who later developed ANV, this relationship was not obtained in other research (5, 8, 34) . Furthermore, contrary to the anxiety-conditionability hypothesis, Andrykowski and Redd (33) found that elevated infusion-related anxiety was associated with a slower development of ANV. Patients who developed ANV during their first four cycles of chemotherapy evidenced a pattern of low, stable anxiety across infusions prior to the development of ANV. On the other hand, patients who developed ANV during their fifth cycle or later evidenced greater anxiety across infusions prior to the development of ANV. In addition, the initial occurrence of ANV was accompanied by a large increase in infusion-related anxiety in later onset patients.
In summary, the anxiety-conditionability hypothesis posits trait anxiety as a predisposing "cause" of ANV with infusion-related state anxiety viewed as a precipitating "cause." Unfortunately, little evidence supports the hypothesis that trait or state anxiety directly facilitates the classical conditioning of ANV. Measures of both trait and state anxiety obtained prior to the development of ANV have not been consistently associated with an increased likelihood or rapidity of ANV development.
It could be argued, however, that the inconsistency of research findings is attributable to methodological variability, such as differences across studies in the assessment of state anxiety or in the patient sample studied. Regarding the latter, Coons et al. (5) studied patients receiving cisplatin-an extremely potent emetic agent. Under conditions of high emeticity, whatever facilitating effect state anxiety has upon the conditioning of ANV could be overwhelmed by the contribution of PNV to the development of these symptoms. If this were so, it would be expected that the facilitative impact of state anxiety could then be best demonstrated under conditions of relatively low emeticity. However, in a sample of breast cancer patients characterized by infrequent instances of post-treatment vomiting and relatively low levels of post-treatment nausea, state anxiety was found to be unrelated to subsequent ANV development (8) . Regarding the assessment of state anxiety, prospective and immediate assessment of infusion-related anxiety is superior to retrospective assessment of anxiety. Thus, the best tests of the anxiety-conditionability hypothesis would be the research by Andrykowski and his colleagues (7, 8, 33) . However, elevated state anxiety was not associated with either an increased likelihood or rapidity of ANV development in the Andrykowski et al. (8) study and it was, in fact, associated with a slower development of ANV in the Andrykowski and Redd study (33) . Thus, even under methodologically optimal conditions, the data consistently fail to support the anxiety-conditionability hypothesis.
Anxiety exacerbates post-treatment nausea and vomiting. According to this hypothesis (33), infusion-related state anxiety serves as an indirect cause of ANV by exacerbating the degree of PNV experienced. Both additive and interactive effects are possible. On the one hand, state anxiety may itself generate some degree of gastrointestinal distress which is simply added to that produced by the emetic stimulus posed by the chemotherapy drugs. Alternatively, state anxiety might interact with this emetic stimulus, perhaps at the neurological level, to produce a heightened gastrointestinal response. In either instance, increased severity of PNV then increases the likelihood that a patient will develop ANV through a simple classical conditioning process.
In contrast to the ANV-anxiety hypothesis which requires that state anxiety and ANV covary, support for this hypothesis requires demonstration of a positive association between infusion-related anxiety and PNV. While the relationship between state anxiety and gastrointestinal distress has been discussed earlier (23) (24) (25) , little research has examined the relationship between state anxiety and PNV. An exception is the study by Jacobsen et al. (51) . Using a multivariate model, they found that state anxiety was associated with a greater prevalence, frequency, and severity of postchemotherapy nausea. Among the cross sectional studies of ANV, only Ingle et al. (15) reported data regarding the relationship between state anxiety and PNV. Consistent with this hypothesis, they found greater state anxiety to be associated with greater PNV. A more convincing demonstration of the nausea-exacerbating effect of state anxiety would require demonstration that increases in infusion-related anxiety precede increases in PNV with increases in the latter preceding onset of ANV. This is precisely the pattern evidenced by patients with a late onset of ANV (i.e., initial onset of ANV following at least four cycles of chemotherapy] in the longitudinal study by Andrykowski and Redd (33) .
In summary, this hypothesis posits infusion-related anxiety as a precipitating "cause" of ANV. While some data suggest that state anxiety is positively associated with PNV, there is as yet only modest support for the hypothesis that state anxiety contributes to the development of ANV by the exacerbation of PNV. Therefore, given that state anxiety has been linked to the experience of nausea in other contexts and that increased PNV has been definitively linked to the occurrence of ANV, it seems reasonable to conclude that for some patients state anxiety can contribute to the development of ANV via the exacerbation of PNV. In particular, this process appears to be most likely to contribute to the development of ANV in patients with an initial onset of ANV relatively later in their course of chemotherapy (8, 33) .
ANV causes anxiety. According to this hypothesis, ANV and state anxiety cooccur in patients but, contrary to previous hypotheses, it is the experience of ANV which causes infusion-related anxiety to develop or increase. More specifically, ANV initially develops through a classical conditioning process which is independent of the patient's experience of infusionrelated anxiety. In fact, patients need not experience any infusion-related anxiety at all. Once ANV develops, however, the physical and psychological distress associated with this symptom produces or exacerbates state anxiety in anticipation of, or during, infusions.
In support of this hypothesis, ample research has demonstrated that patients who report ANV are more anxious and distressed than other patients (7, 8, (12) (13) (14) (15) . However, these results are correlational and cannot, of course, distinguish whether such state anxiety results from ANV or vice versa. Support for this hypothesis would require demonstration of increases in infusion-related anxiety or distress after an initial occurrence of ANV. Even then, however, the possibility that state anxiety causally contributed to the development of ANV to at least some degree still could not be ruled out unless it could be shown that infusion-related anxiety first occurred following the initial occurrence of ANV. Unfortunately, no research has ever examined state anxiety levels across infusions both prior to and following the initial onset of ANV. However, Andrykowki and Redd (33) did examine state anxiety across infusions prior to and including the infusion at which ANV was first reported. Consistent with the ANV-causes-anxiety hypothesis, they found that state anxiety at the infusion of ANV onset was markedly elevated relative to the previous two infusions. However, inconsistent with this hypothesis, they found some evidence for increases in state anxiety across the two infusions preceding the infusion of onset.
In sum, it is reasonable to assume that ANV can contribute to the anxiety or distress associated with chemotherapy. In this sense, ANV can serve as a precipitating or maintaining "cause" of infusionrelated anxiety. However, no evidence supports the contention that the tendency for state anxiety and ANV to co-occur in many patients is strictly due to the anxiety-engendering capacity of ANV. Rather, any causal relationship between state anxiety and ANV is likely bi-directional. In addition, it should be noted that any increases in state anxiety engendered by ANV could then be causally related to the further conditioning and experience of ANV.
Artifactual Relationships Between ANV and Anxiety
In addition to the causal hypotheses described above, it is possible that the observed relationship between ANV and state anxiety might be more artifact than actuality. For example, because ANV and state anxiety are typically assessed via self-report, some degree of correspondence between these variables should result simply because of shared method variance. Concurrent reports of infusion-related anxiety and ANV could simply reflect a tendency for patients to report a variety of distressing symptoms. In the extreme, neither state anxiety nor ANV may actually be present. Alternatively, one or the other may be present in a patient. However, both symptoms are reported because of an underlying bias to respond in the affirmative when queried regarding the experience of various symptoms.
Reports of ANV and state anxiety also might co-occur because of a failure to clearly distinguish sensations of nausea from sensations of anxiety (32) . Both anxiety and nausea are private, subjective phenomena which are typically assessed by self-report. Because nausea can be a concomitant of the stress response, it might be difficult for some patients to distinguish nausea from anxiety. This might be particularly true for lesser magnitudes of each since behavioral indicants that could facilitate accurate labeling of physiological sensations as either nausea or anxiety are missing or obscure. As a result, patients who are anxious prior to an infusion might correctly report such but also might inaccurately report that they are experiencing ANV. This mislabeling can also occur in the opposite direction as well; an accurate report of ANV might be accompanied by an inaccurate report of pretreatment state anxiety.
Evaluation of the extent to which such artifacts might account for the observed relationship between ANV and state anxiety is difficult. Some degree of correspondence between ANV and state anxiety is consistent with several of the causal hypotheses described above and therefore is to be expected. Thus, although Andrykowski (32) reported intercorrelations of 0.42 and 0.69 between pretreatment state anxiety and nausea ratings in two groups of patients with pretreatment nausea, one is unable to ascertain the degree to which these correlations reflect shared method variance, a symptom-reporting bias, difficulty in distinguishing between ANV and anxiety, or the actual co-occurrence of these symptoms. This problem could be circumvented by the addition of observational or physiological measures of either ANV or state anxiety to the research in this area. Alternatively, or in addition, researchers could eliminate the difficulties posed by self-report by focusing exclusively upon the relationship between state anxiety and anticipatory vomiting. However, since the prevalence of anticipatory vomiting is much lower than that of anticipatory nausea, patient accrual would pose an obvious problem. A less obvious concern would be that the relationship between state anxiety and , anticipatory nausea might differ from that between state anxiety and anticipatory vomiting. Thus, in trying to reduce the methodological problems associated with the study of a relatively common phenomenon (i.e., anticipatory nausea) one risks obtaining results that are potentially confined to a much less common phenomenon (i.e., anticipatory vomiting).
Summary and Recommendations for Future Research
Although five hypotheses have been suggested, the relationship between ANV and anxiety has not been definitively established. Unfortunately, whenever both ANV and anxiety are assessed by selfreport, it is difficult to unequivocably refute the hypothesis that methodological artifacts account for any observed relationship between ANV and anxiety. Apart from this, sufficient evidence suggests that infusion-related state anxiety contributes to the development of ANV in at least some patients. While the data do not clearly rule out the possibility that anxiety facilitates the classical conditioning of ANV, the evidence is not strong in support of this hypothesis either. Similarly, while some instances of ANV might be a simple concomitant of pretreatment anxiety, the data suggest that this is an inadequate explanation for most instances of ANV. Most consistent with the available data is the hypothesis that anxiety serves as a precipitating cause of ANV by exacerbating PNV. Even here, however, the data are far from definitive in their support of this hypothesis.
In large part the lack of definitive support for one or the other of the hypothesized ANV-anxiety relationships is due to the fact that the research in this area has not been designed to untangle these hypotheses. To accomplish this, future research must utilize a prospective and longitudinal research design. A sample size sufficient to ensure adequate statistical power should be enlisted. Measures of pretreatment nausea, PNV, and infusionrelated anxiety should be obtained at each infusion. The amount of retrospection required in the assessment of these variables should be minimized. If possible, assessment of nausea and vomiting should be multimodal, incorporating physiological and/or observational indices in addition to the typical self-report measures. ANV must be defined to exclude instances of anticipatory symptoms which are attributable to physiological factors or recent oral or intravenous medications (39) . When analyzing data, patients with anticipatory nausea should be separated from those with anticipatory vomiting, since anxiety might be differentially related to each. Finally, assessment of patients should continue even after their first experience of ANV, in order to further evaluate the degree to which ANV and anxiety covary across infusions.
CLINICAL IMPLICATIONS AND RECOMMENDATIONS
Irregardless of the causal process presumed to underly the ANV-anxiety relationship, it might be expected that reduction of infusion-related anxiety could serve to eliminate, reduce, or prevent ANV in some patients. Empirical support for this assertion is by and large indirect, however. Thus recommendations for controlling ANV through anxiety reduction should be viewed as speculative and in need of substantiation. For example, while behavioral procedures such as hypnosis (52) and progressive muscle relaxation with guided imagery (53) have been shown to be effective in eliminating or reducing ANV, both of these procedures involve induction of physiological relaxation prior to and during infusions. Thus, the effectiveness of these procedures in controlling ANV cannot be attributed solely to anxiety reduction. Both also incorporate cognitive distraction, which by itself can be effective in the treatment of ANV (54) .
Procedures identical to those used in the behavioral treatment of ANV also have been shown to be effective in preventing the development of ANV (18) . In this study, first time chemotherapy patients receiving highly emetogenic regimens were randomly assigned to either a relaxation-training or a no relaxationtraining (i.e., control) group. Patients in the relaxation-training group received one to three training sessions prior to their initial chemotherapy infusion. Patients received training in the use of progressive muscle relaxation in conjunction with guided relaxation imagery (53) . Patients then used this relaxation technique immediately prior to and during their first five infusions. Implementation during the first few infusions was assisted by a therapist whose involvement was gradually reduced so that by the fifth infusion patients were self-administering the relaxation procedure. Pre-and post-infusion assessments indicated that relaxation training had a significant anti-anxiety effect: patients in the relaxation group exhibited lower pulse rates and blood pressure and reported less state anxiety than patients in the control group. In addition, patients in the relaxation group reported less nausea and vomiting during infusions as well as during the 72 hours following infusions. It was concluded that relaxation training can prevent the development of ANV. However, as discussed previously, while anxiety-reduction is a likely mechanism, the confounding of relaxation and cognitive distraction precludes unambiguous attribution of the preventive impact of this intervention to anxiety-reduction.
In addition to being a reliable by-product of behavioral procedures used in the treatment and prevention of ANV, reduction of infusion-related anxiety might be accomplished through other means. The simplest, perhaps, is appropriate use of standard pharmacological anti-anxiety agents. A less simpler means of reducing infusion-related anxiety involves reduction of the potential aversiveness of the procedures involved in chemotherapy administration. For example, considerable distress is often associated with venipuncture procedures. Venipuncture is more difficult when the patient is anxious or when the patient's veins have been compromised by previous venipuncture placements. The need for multiple needle sticks under these circumstances can exacerbate existing levels of infusion-related anxiety. The aversiveness associated with infusions can then promote a spiraling effect across infusions as the patient experiences anxiety in anticipation of subsequent infusions. A variety of behavioral strategies, such as relaxation, cognitive control and distraction, and hypnosis, have been shown to be effective in reducing venipuncture distress in pediatric oncology patients (55) (56) (57) . Extension of these procedures, along with those effective in reducing distress associated with other medical procedures (e.g., bone marrow aspirations and spinal taps (58)), to the management of venipuncture distress in adults appears straightforward.
Finally, reduction of infusion-related state anxiety can potentially be accomplished through engineering of the physical environment in which chemotherapy is administered. Chemotherapy clinics differ in their physical characteristics and some research has suggested that differ-ences might be linked to differences in ANV prevalence across treatment sites (13, 59) . More specifically, clinics differ in the degree to which patients are afforded privacy during their infusions. Patients can receive their infusions in large group treatment rooms or in separate rooms or cubicles. The former setting could increase infusion-related anxiety in some patients as a result of observing other patients who might be experiencing psychological or gastrointestinal distress. On the other hand, increased opportunity for interaction with other patients and families afforded by the group treatment setting could reduce anxiety for some patients, perhaps by serving as a distraction from anxious rumination. Availability of both types of treatment settings as well as flexibility in responding to the preferences of individual patients can potentially reduce the incidence and magnitude of infusionrelated anxiety. In addition, clinic facilities differ in the extent to which patients are exposed to potential anxiety-generating cues in the treatment environment. Some clinics, particularly those with group treatment rooms as described above, have work stations where staff mix and prepare chemotherapy drugs in full view of patients. Again, individual differences exist, but clearly some patients will be distressed by this increased exposure to drug odors or the sight of syringes, drugs, or other infusion-related apparatus.
Summary
Several mechanisms by which state anxiety can contribute to the development and experience of ANV have been identified. Although firm empirical support for any specific hypothesis linking ANV with state anxiety has not been established, efforts to reduce infusion-related anxiety are likely to result in at least some reduction in the incidence and magnitude of ANV and are thus to be recommended. In particular, a proactive, as opposed to reactive, approach to anxiety reduction is most likely to be beneficial. There are at least two reasons for this. First, in the chemotherapy setting, it is likely that anxiety produces not only more anxiety, but more gastrointestinal distress as well. The latter, in turn, likely increases infusion-related anxiety and distress, thus creating an ever-worsening cycle of increasing chemotherapy-related distress and increased risk for developing ANV. Second, some evidence suggests that the effectiveness of behavioral interventions in treating ANV is compromised in patients with moderate to high levels of state anxiety (60) . Contrary to expectation, patients with the lowest levels of infusion-related anxiety evidenced the largest reductions in physiological arousal and psychological distress following behavioral treatment for ANV. Thus, elevated state anxiety has been linked to both a greater risk for developing, but also to a reduced efficacy of behavioral interventions for treating, ANV. It must be concluded, therefore, that efforts to reduce the incidence and severity of ANV by the prevention or minimization of infusion-related state anxiety are most likely to be successful when they are initiated at the beginning of a patient's course of chemotherapy.
